Abstract

Since the early studies of Deutsch (1), the non-selective muscarinic receptor antagonist scopolamine has been used as a drug that impairs memory performance in man. The notion that scopolamine could be used as a pharmacological model of age-associated memory impairment and dementia further strengthened the cholinergic hypothesis of geriatric memory dysfunction by Bartus et al. (2). Since then, a vast amount of studies applied this model to induce memory impairments in young healthy subjects to model age-related memory disorders. At present, scopolamine is still considered to be the best model for inducing cognitive impairments in healthy subjects (3). Scopolamine is therefore used as a pharmacological model to test novel cognition-enhancing drugs in animals [e.g., Ref. (4–6)] and in humans [e.g., Ref. (7, 8)]. In clinical trials, scopolamine is in particular being used as a model for AD in which novel cognition-enhancing drugs are tested (see https://ClinicalTrials.gov).

Highlights

  • Reviewed by: Antonio Pisani, University of Rome Tor Vergata, Italy Santiago J

  • The notion that scopolamine could be used as a pharmacological model of age-associated memory impairment and dementia further strengthened the cholinergic hypothesis of geriatric memory dysfunction by Bartus et al [2]

  • Scopolamine is considered as a golden standard for cholinergic deficits and the existing data were used as a reference for evaluating novel cognition-enhancing drugs

Read more

Summary

Introduction

Reviewed by: Antonio Pisani, University of Rome Tor Vergata, Italy Santiago J. Since the early studies of Deutsch [1], the non-selective muscarinic receptor antagonist scopolamine has been used as a drug that impairs memory performance in man. Scopolamine is used as a pharmacological model to test novel cognition-enhancing drugs in animals [e.g., Ref. Further efforts have been made to compare human and animal data with scopolamine to further validate the scopolamine as a model of cognitive impairments.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.